Sandoz Announces Leadership Transition as Francisco Ballester Retires, Peter Stenico to Lead Region International

Sandoz Announces Leadership Transition as Francisco Ballester Retires, Peter Stenico to Lead Region International

(IN BRIEF) Sandoz has announced the retirement of Francisco Ballester, President of Region International, after 34 years of service, effective March 1, 2025. Francisco has been instrumental in expanding business growth and patient access in markets outside North America and Europe. He will be succeeded by Peter Stenico, currently the Global Platform Head of Biosimilars and Country President of Sandoz Austria. Peter, who joined Sandoz in 2002, has held various leadership roles and brings extensive experience in biosimilars and generics. Richard Saynor, CEO of Sandoz, expressed gratitude for Francisco’s contributions and welcomed Peter to lead Region International, confident in his ability to drive the next phase of growth.

(PRESS RELEASE) BASEL, 3-Feb-2025 — /EuropaWire/ — Sandoz, a global leader in generic and biosimilar medicines, has announced that Francisco Ballester, President of Region International and a member of the Sandoz Executive Committee, will retire on March 1, 2025, after 34 years of dedicated service. Since 2019, Francisco has played a key role in driving business growth and improving patient access to medicines in markets outside North America and Europe. He has also been instrumental in fostering diverse talent in the region. Additionally, Francisco is a member of the Health Management and Policy Advisory Council at the Miami Herbert Business School.

Peter Stenico, currently serving as the Global Platform Head for Biosimilars and Country President of Sandoz Austria, will succeed Francisco. Peter has been with Sandoz since 2002 and brings a wealth of experience in biosimilars and generics. He joined the company in 2002 and has held various leadership positions, including Country Head and General Manager for Sandoz in Germany, as well as President of the German Generics Association (Pro Generika). In his current role, Peter has successfully led Sandoz’s global biosimilar strategy.

Richard Saynor, CEO of Sandoz, commented, “Francisco has dedicated his entire career to Sandoz, taking on numerous leadership roles with a commitment that has driven the company’s growth. His passion, dedication, and invaluable contributions to the Sandoz Executive Committee will be missed, and I wish him a fulfilling retirement.”

Saynor also expressed pride in Sandoz’s leadership bench, highlighting Peter’s long tenure at the company and his vast experience in the generics and biosimilars industries. He welcomed Peter to his new role, confident that he will take Sandoz Region International to new heights of success and growth.

DISCLAIMER
This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.

ABOUT SANDOZ
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 800 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,500 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2023, Sandoz recorded net sales of USD 9.6 billion.

Media Contacts:

SOURCE: Sandoz